Clinical Trial Update: A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014) [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics study assessing vibegron (MK-4618) in participants with renal insufficiency to understand dosing considerations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Vibegron (vibegron)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Overactive Bladder | Phase 1 | Status: COMPLETED | Results posted: 2016-08-09